With Am­gen hot on its heels, Ra­dius races to get a jump on os­teo­poro­sis drug ri­val­ry

This week, Ra­dius Health $RDUS will open a brand new chap­ter in its his­to­ry, armed with an FDA ap­proval for its os­teo­poro­sis drug Tym­los (abaloparatide).

Ra­dius is launch­ing its very first drug on­to the mar­ket, about to set the price on their ther­a­py (that ar­rives ear­ly Mon­day) and map­ping out a com­mer­cial strat­e­gy that will have to take in­to ac­count Eli Lil­ly’s ag­ing For­teo with the ri­val ro­mosozum­ab from Am­gen and UCB be­ing steered in­to a Ju­ly 19 PDU­FA date.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.